This website is intended for healthcare professionals only.
3rd-LINE THERAPY IN mCRC, INSIGHTS FROM DAILY CLINICAL PRACTICE
Prof Julien Taieb MD, PhD Head of the Gastroenterology and Gastrointestinal Oncology Department, Georges Pompidou - European Hospital, Paris
This webinar presents the main treatment option for metastatic colorectal cancer (mCRC), from 1L to 3L with a focus on 3L. In addition to prognostic factors, It highlights 3L therapeutic objectives and shows the benefits of mCRC treatments, such as FTD/TPI, in OS, PFS, ECOG PS and QoL. A clinical case based on the expert's clinical experience discusses treatment strategy and selection through 3L.
Key points covered
This webinar highlights the objectives of mCRC treatments in 3L and the advantages of FTD/TPI in terms of efficacy, safety, and quality of life.
In mCRC, the continuum of care with validated treatment options in 3L is central
Disease- and patient-related factors, as well as prior treatments, are essential to choose the best therapeutic strategy in later lines.
Webinar Replay
Featured Speaker
Prof Julien Taieb
Julien Taieb, MD, PhD is currently the Head of the Gastroenterology and Gastrointestinal Oncology Department at the Georges Pompidou European Hospital, Paris, France. He is a member of a several French and international medical organizations, including a position on the scientific committee of ESMO. Professor Taieb is involved in particular in clinical trials, leading more than 10 national and international phase II and III studies, and in translational research related to his main research interests: nonmetastatic, metastatic and metastatic colon cancer and pancreatic cancer. He is an expert in his field, with more than 300 peer-reviewed publications and 500 meeting abstracts.
